These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 12846271

  • 1. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
    [Abstract] [Full Text] [Related]

  • 2. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [Abstract] [Full Text] [Related]

  • 3. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
    Tofteng CL, Kindmark A, Brändström H, Abrahamsen B, Petersen S, Stiger F, Stilgren LS, Jensen JE, Vestergaard P, Langdahl BL, Mosekilde L, Danish Osteoporosis Prevention Study.
    Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
    [Abstract] [Full Text] [Related]

  • 5. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
    Heikkinen AM, Niskanen LK, Salmi JA, Koulu M, Pesonen U, Uusitupa MI, Komulainen MH, Tuppurainen MT, Kröger H, Jurvelin J, Saarikoski S.
    Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
    [Abstract] [Full Text] [Related]

  • 6. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
    [Abstract] [Full Text] [Related]

  • 7. Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?
    Heikkinen AM, Kröger H, Niskanen L, Komulainen MH, Ryynänen M, Parviainen MT, Tuppurainen MT, Honkanen R, Saarikoski S.
    Maturitas; 2000 Jan 15; 34(1):33-41. PubMed ID: 10687880
    [Abstract] [Full Text] [Related]

  • 8. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S.
    J Clin Endocrinol Metab; 1997 Aug 15; 82(8):2476-82. PubMed ID: 9253321
    [Abstract] [Full Text] [Related]

  • 9. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Aug 15; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Jurvelin J, Saarikoski S.
    J Clin Endocrinol Metab; 1999 Feb 15; 84(2):546-52. PubMed ID: 10022414
    [Abstract] [Full Text] [Related]

  • 12. A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk.
    Zarrabeitia MT, Hernández JL, Valero C, Zarrabeitia AL, García-Unzueta M, Amado JA, González-Macías J, Riancho JA.
    Eur J Endocrinol; 2004 May 15; 150(5):699-704. PubMed ID: 15132727
    [Abstract] [Full Text] [Related]

  • 13. Aerobic exercise and bone mineral density in middle-aged finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor alpha gene polymorphisms.
    Remes T, Väisänen SB, Mahonen A, Huuskonen J, Kröger H, Jurvelin JS, Penttilä IM, Rauramaa R.
    Bone; 2003 Apr 15; 32(4):412-20. PubMed ID: 12689685
    [Abstract] [Full Text] [Related]

  • 14. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S.
    Osteoporos Int; 2000 Apr 15; 11(3):211-8. PubMed ID: 10824236
    [Abstract] [Full Text] [Related]

  • 15. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.
    Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML.
    J Clin Endocrinol Metab; 2004 Jun 15; 89(6):2803-10. PubMed ID: 15181061
    [Abstract] [Full Text] [Related]

  • 16. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.
    Komulainen MH, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Saarikoski S.
    Maturitas; 1998 Nov 30; 31(1):45-54. PubMed ID: 10091204
    [Abstract] [Full Text] [Related]

  • 17. Relation of estrogen receptor-alpha gene polymorphism and hormone replacement therapy to fall risk and muscle strength in early postmenopausal women.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Partanen J, Mäenpää PH.
    Ann Med; 2002 Nov 30; 34(1):64-72. PubMed ID: 12014437
    [Abstract] [Full Text] [Related]

  • 18. CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post-menopausal women to hormonal replacement therapy.
    Masi L, Ottanelli S, Berni R, Cacudi E, Giusti F, Marcucci G, Cavalli L, Fossi C, Marini F, Ciuffi S, Tanini A, Brandi ML.
    Clin Cases Miner Bone Metab; 2014 Jan 30; 11(1):36-43. PubMed ID: 25002878
    [Abstract] [Full Text] [Related]

  • 19. Association of the (TTTA)n repeat polymorphism of CYP19 gene with bone mineral density in Greek peri- and postmenopausal women.
    Markatseli AE, Lazaros L, Markoula S, Kostoulas H, Sakaloglou P, Tigas S, Georgiou I, Tsatsoulis A.
    Clin Endocrinol (Oxf); 2014 Jul 30; 81(1):38-44. PubMed ID: 24621381
    [Abstract] [Full Text] [Related]

  • 20. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study.
    Komulainen M, Tuppurainen MT, Kröger H, Heikkinen AM, Puntila E, Alhava E, Honkanen R, Saarikoski S.
    Osteoporos Int; 1997 Jul 30; 7(2):126-32. PubMed ID: 9166392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.